Bictegravir
Sponsors
Gilead Sciences, Fenway Community Health, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, ViiV Healthcare, Instituto Mexicano del Seguro Social
Conditions
Antiretroviral TreatmentHIVHIV InfectionHIV InfectionsHIV PreventionHIV-1 InfectionHIV-1-infectionMetabolic Cardiovascular Syndrome
Phase 1
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants
CompletedNCT02275065
Start: 2014-10-24End: 2015-01-29Updated: 2020-11-09
Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function
CompletedNCT02400307
Start: 2015-04-17End: 2015-07-13Updated: 2019-10-11
Phase 2
Phase 3
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
Active, not recruitingNCT05979311
Start: 2024-02-09End: 2027-02-23Updated: 2025-12-05
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
Active, not recruitingNCT06333808
Start: 2024-03-25End: 2029-12-31Updated: 2025-11-05
Phase 4
Unknown Phase
Gut Microbiota, PGx and INSTIs Response
CompletedNCT04805944
Start: 2021-03-10End: 2023-12-31Updated: 2024-05-10
Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN
CompletedNCT06629480
Start: 2021-06-25End: 2024-02-28Updated: 2024-10-08